-
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
Handoffs have been extensively examined as a potential source of communication failure. Such studies typically focus on how to best share details of care when patient responsibility is transferred from one clinical care team to another.
-
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
-
-
Five days of steroid treatment was as effective as 14 days of treatment in preventing repeat exacerbations of COPD in patients presenting to the emergency department with COPD exacerbations.
-
The injection of a dextrose solution in and around the knee (prolotherapy) is an alternative treatment for the pain of knee osteoarthritis. A randomized, controlled trial shows that prolotherapy is effective for long-term control of knee pain and improvement in knee function.
-
